Literature DB >> 17854662

HMGA2 expression in a canine model of prostate cancer.

Susanne Winkler1, Hugo Murua Escobar, Britta Meyer, Daniela Simon, Nina Eberle, Wolfgang Baumgartner, Siegfried Loeschke, Ingo Nolte, Jörn Bullerdiek.   

Abstract

Prostate cancer is the most prevalent cancer in western countries, being the third leading cause of male cancer death. To check its possible significance as a prognostic marker, allowing a better prognosis of the tumor, we analyzed the high-mobility group protein-A2 gene (HMGA2) expression level because HMGA2 overexpression has been shown to correlate with the malignant potential of various neoplasias. Aside from man, the dog is the only mammalian species that shows spontaneously occurring prostate carcinoma with striking similarities to prostate cancer growth and progression in man, making it an adequate animal model for this neoplasia. We used real-time quantitative reverse-transcription polymerase chain reaction for HMGA2 expression analyses in a subset of canine prostate tissue samples. Our investigations reveal that HMGA2 expression levels in all carcinomas were higher than those of any of the nonmalignant tissues. Thus, canine prostate cancer represents a spontaneously occurring model to test therapeutic effects resulting from reduced expression of HMGA2.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17854662     DOI: 10.1016/j.cancergencyto.2007.06.008

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  11 in total

1.  High mobility group A2 (HMGA2) promotes EMT via MAPK pathway in prostate cancer.

Authors:  Ohuod Hawsawi; Veronica Henderson; Liza J Burton; Jodi Dougan; Peri Nagappan; Valerie Odero-Marah
Journal:  Biochem Biophys Res Commun       Date:  2018-09-01       Impact factor: 3.575

2.  Probing into the biological processes influenced by ESC factor and oncoprotein HMGA2 using iPSCs.

Authors:  Amir Morshedi; Zhonglu Ren; Jinming Li; Peter Dröge
Journal:  Stem Cell Rev Rep       Date:  2013-08       Impact factor: 5.739

3.  miR-154 inhibits EMT by targeting HMGA2 in prostate cancer cells.

Authors:  Chen Zhu; Jie Li; Gong Cheng; Hai Zhou; Liangjun Tao; Hongzhou Cai; Pu Li; Qiang Cao; Xiaobing Ju; Xiaoxin Meng; Meilin Wang; Zhengdong Zhang; Chao Qin; Lixin Hua; Changjun Yin; Pengfei Shao
Journal:  Mol Cell Biochem       Date:  2013-04-17       Impact factor: 3.396

4.  Characterization of nanoparticle mediated laser transfection by femtosecond laser pulses for applications in molecular medicine.

Authors:  Markus Schomaker; Dag Heinemann; Stefan Kalies; Saskia Willenbrock; Siegfried Wagner; Ingo Nolte; Tammo Ripken; Hugo Murua Escobar; Heiko Meyer; Alexander Heisterkamp
Journal:  J Nanobiotechnology       Date:  2015-02-03       Impact factor: 10.435

Review 5.  Role of miRNA let-7 and its major targets in prostate cancer.

Authors:  Siegfried Wagner; Anaclet Ngezahayo; Hugo Murua Escobar; Ingo Nolte
Journal:  Biomed Res Int       Date:  2014-09-03       Impact factor: 3.411

Review 6.  HMGA2 as a Critical Regulator in Cancer Development.

Authors:  Behzad Mansoori; Ali Mohammadi; Henrik J Ditzel; Pascal H G Duijf; Vahid Khaze; Morten F Gjerstorff; Behzad Baradaran
Journal:  Genes (Basel)       Date:  2021-02-13       Impact factor: 4.096

7.  Molecular signatures of prostate stem cells reveal novel signaling pathways and provide insights into prostate cancer.

Authors:  Roy Blum; Rashmi Gupta; Patricia E Burger; Christopher S Ontiveros; Sarah N Salm; Xiaozhong Xiong; Alexander Kamb; Holger Wesche; Lisa Marshall; Gene Cutler; Xiangyun Wang; Jiri Zavadil; David Moscatelli; E Lynette Wilson
Journal:  PLoS One       Date:  2009-05-29       Impact factor: 3.240

8.  Generation and characterisation of a canine EGFP-HMGA2 prostate cancer in vitro model.

Authors:  Saskia Willenbrock; Siegfried Wagner; Nicola Reimann-Berg; Mohammed Moulay; Marion Hewicker-Trautwein; Ingo Nolte; Hugo Murua Escobar
Journal:  PLoS One       Date:  2014-06-10       Impact factor: 3.240

9.  HMGA1 and HMGA2 expression and comparative analyses of HMGA2, Lin28 and let-7 miRNAs in oral squamous cell carcinoma.

Authors:  Katharina Anna Sterenczak; Andre Eckardt; Andreas Kampmann; Saskia Willenbrock; Nina Eberle; Florian Länger; Sven Kleinschmidt; Marion Hewicker-Trautwein; Hans Kreipe; Ingo Nolte; Hugo Murua Escobar; Nils Claudius Gellrich
Journal:  BMC Cancer       Date:  2014-09-23       Impact factor: 4.430

10.  TiHo-0906: a new feline mammary cancer cell line with molecular, morphological, and immunocytological characteristics of epithelial to mesenchymal transition.

Authors:  José Luis Granados-Soler; Johannes Junginger; Marion Hewicker-Trautwein; Kirsten Bornemann-Kolatzki; Julia Beck; Bertram Brenig; Daniela Betz; Jan Torben Schille; Hugo Murua Escobar; Ingo Nolte
Journal:  Sci Rep       Date:  2018-09-05       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.